Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Residual Diabetic Macular Edema Following Bevacizumab
NCT01253694Phase 2Withdrawn
- Start
- Mar 2011
- Primary completion
- Jun 2012
- Countries
- 1
01
Overview
Phase 2, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms). Primary endpoint: Proportion of subjects with resolution of diabetic macular edema at 6 months. Planned start Mar 2011; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01253694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253694.